BioLineRx To Present Pre-Clinical Data Demonstrating Strong Synergy Between GLIX1 And Various PARP Inhibitors In HR-Proficient Ovarian Cancer Cell Lines At The 2026 European Society For Medical Oncology Annual Meeting In October

Bioline RX Ltd Sponsored ADR

BLRX

0.00

Presentation Details:

Title: GLIX1, a TET2 Activator Targeting the DNA Damage Response, Synergizes with PARP Inhibitors in Ovarian Cancer Cell Lines

Presentation #: 1435eP

Presentation type: e-Poster

Location: e-Poster Area, Hall 25

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.